193 Differences in thyroid immune-related adverse events between lung cancer types, a retrospective analysis

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A208-A208
Author(s):  
Rahim Jiwani ◽  
Heather Brody ◽  
Yuxuan Mao ◽  
Elisabeth Lee ◽  
Rita Rehana ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Thyroid Dysfunction ◽  
Cohort Analysis ◽  
Cancer Type ◽  
Chi Square ◽  
Cancer Types

BackgroundImmune modulation of the PD-1/PD-L1 pathway is a promising treatment of various malignancies however, alteration of the pathway is known to cause many immune related adverse events (irAEs) including thyroid dysfunction. Whether the frequency of thyroid irAEs differ between lung cancer types has not yet been studied.MethodsA total of three hundred twenty-nine lung cancer patients treated with immunotherapy at East Carolina University between April 2014 and July 2019 were included in a retrospective cohort analysis. Baseline TSH and TSH at each treatment cycle were recorded along with the type of lung cancer, specific agent used, timing of thyroid dysfunction and need for levothyroxine replacement. The frequency of thyroid irAEs as defined by TSH < 0.4 or > 4.0 and its relationship with lung cancer types were analyzed using chi square tests and logistic regression.ResultsOf the three hundred twenty-nine patients; 54.4% had adenocarcinoma, 31.6% had squamous cell carcinoma, 11.3% had small cell carcinoma and 2.7% had poorly differentiated lung cancer. Overall, 135 patients (41.0%) developed thyroid irAEs (table 1). Pearson’s chi square test was used to compare the frequencies of thyroid irAEs for each type of lung cancer against all other lung cancer types. Patients with squamous cell carcinoma developed significantly less thyroid irAEs (32.7%), compared to all other lung cancers (44.9%), X2 (1, N = 329) = 4.4, p = 0.037. Conversely, patients with lung cancer types other than squamous cell carcinoma were more likely to develop thyroid irAEs, OR = 1.68 (95% CI: 1.03 – 2.73).ConclusionsThyroid irAEs occurred significantly less frequently in patients with squamous cell carcinoma than those with other lung cancer types. This analysis may allow clinicians to better identify patients more likely to develop irAE thyroid dysfunction based on lung cancer type.Abstract 193 Table 1Frequency of lung cancer type and thyroid dysfunction within each group

scholarly journals Integrated Analysis of MicroRNA (miRNA) and mRNA Profiles Reveals Reduced Correlation between MicroRNA and Target Gene in Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-15 ◽  
Author(s):  
Xingsong Li ◽  
Xiaokang Yu ◽  
Yuting He ◽  
Yuhuan Meng ◽  
Jinsheng Liang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Mirna Target ◽  
Target Gene ◽  
Target Genes ◽  
Integrated Analysis ◽  
Cancer Type ◽  
Gene Pairs ◽  
Cancer Types

Background. Accumulating evidences demonstrated that microRNA-target gene pairs were closely related to tumorigenesis and development. However, the correlation between miRNA and target gene was insufficiently understood, especially its changes between tumor and normal tissues. Objectives. The aim of this study was to evaluate the changes of correlation of miRNAs-target pairs between normal and tumor. Materials and Methods. 5680 mRNA and 5740 miRNA expression profiles of 11 major human cancers were downloaded from the Cancer Genome Atlas (TCGA). The 11 cancer types were bladder urothelial carcinoma, breast invasive carcinoma, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, stomach adenocarcinoma, and thyroid carcinoma. For each cancer type, we firstly obtained differentially expressed miRNAs (DEMs) and genes (DEGs) in tumor and then acquired critical miRNA-target gene pairs by combining DEMs, DEGs and two experimentally validated miRNA-target interaction databases, miRTarBase and miRecords. We collected samples with both miRNA and mRNA expression values and performed a correlation analysis by Pearson method for miRNA-target pairs in normal and tumor, respectively. Results. We totally got 4743 critical miRNA-target pairs across 11 cancer types, and 4572 of them showed weaker correlation in tumor than in normal. The average correlation coefficients of miRNA-target pairs were different greatly between normal (-0.38 ~ -0.61) and tumor (-0.04 ~ -0.26) for 11 cancer type. The pan-cancer network, which consisted of 108 edges connecting 35 miRNAs and 89 target genes, showed the interactions of pairs appeared in multicancers. Conclusions. This comprehensive analysis revealed that correlation between miRNAs and target genes was greatly reduced in tumor and these critical pairs we got were involved in cellular adhesion, proliferation, and migration. Our research could provide opportunities for investigating cancer molecular regulatory mechanism and seeking therapeutic targets.

scholarly journals Lung cancer in combined pulmonary fibrosis and emphysema: a large retrospective cohort analysis

2020 ◽  
Vol 6 (4) ◽  
pp. 00521-2020
Author(s):  
Faria Nasim ◽  
Teng Moua
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Pulmonary Fibrosis ◽  
Cell Carcinoma ◽  
Surgical Resection ◽  
Squamous Cell ◽  
Retrospective Cohort ◽  
Cohort Analysis ◽  
Lower Lobe ◽  
Nonsmall Cell Lung Cancer

BackgroundCombined pulmonary fibrosis and emphysema (CPFE) is characterised by upper lobe emphysema and lower lobe fibrosis. Our study aim was to determine the incident risk, presenting characteristics and outcome of lung cancer diagnoses in a cohort of CPFE patients over time.Materials and methodsWe conducted a retrospective cohort study assessing patients with radiological CPFE followed over a median of 76 months (range 1–237 months). Interval development of lung cancer and clinicopathological characteristics of those with and without lung cancer were compared and survival analysis performed.ResultsLung cancer occurred in 26 (11.6%) out of 230 CPFE patients, dominated by nonsmall cell lung cancer (88%, n=23) with squamous cell carcinoma comprising the majority (57%, n=13). There was a predominance of lower lobe (62%) and subpleural (64%) radiological presentation. Survival was reduced for the whole cohort by lung cancer even after adjusting for a priori covariables of age, sex, smoking pack-years, presenting forced vital capacity and radiological honeycombing. Univariable predictors of increased mortality after lung cancer diagnosis included honeycombing (hazard ratio (HR) 3.03, 95% CI 1.16–7.91; p=0.02) and later stage presentation (HR 4.77, 95% CI 1.8–14.94; p=0.001), with those able to undergo surgical resection having better survival (HR 0.29, 95% CI 0.09–0.87; p=0.02).ConclusionLung cancer occurred in 26 (11.6%) out of 230 CPFE patients and was dominated by squamous cell carcinoma presenting in a lower lobe peripheral distribution. Surgical resection appeared to improve survival in selected patients with earlier stage disease. Further studies are needed to develop a relevant screening programme for CPFE patients.

PIK3CA-TP53 co-mutation as a biomarker of overall survival in malignant tumor.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15001-e15001
Author(s):  
Hongyan Wang ◽  
Xiaopeng Zhao ◽  
Xu He ◽  
Miao Wang ◽  
Haoran Zhang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Double Mutant ◽  
Malignant Tumors ◽  
Single Gene ◽  
Hazard Ratio ◽  
Cancer Type ◽  
Cancer Types

e15001 Background: Overall survival (OS) is an important endpoint, with the advantage that there is minimal ambiguity in defining an OS event; the patient is either alive or dead. Some single gene mutations, such as TP53, were identified as important predictors of shorter OS in malignant tumors. However, the relationship between gene co-mutation and OS of malignant tumors is poorly defined. Methods: Genomic and OS data were derived from The Cancer Genome Atlas (TCGA) databases. We defined the double-mutant gene pair as “hit pair” in the specific cancer type if statistically significant OS difference was observed in at least one of three comparison (double-mutant samples vs gene A-only-mutant samples; double-mutant samples vs gene B-only-mutant samples; gene A-only-mutant samples vs gene B-only-mutant samples). Results: PIK3CA-TP53 co-mutation was evaluated as “hit pair” in seven cancer types: GBM (Glioblastoma multiforme), HNSC (Head and neck squamous cell carcinoma), LUSC (Lung squamous cell carcinoma), SARC (Sarcoma), SKCM (Skin cutaneous melanoma), UCEC (Uterine corpus endometrial carcinoma), and UCS (Uterine carcinosarcoma). In SARC and SKCM, the expected hazard ratio was higher in both-mutant group than TP53-only-mutant group, and neither genes were correlated with OS. Especially in SKCM, after we took “neither” group (both genes were wild-type) into comparison, hazard ratio of both-mutant group was significantly higher than neither group. Single-gene mutation didn’t make difference on hazard ratio, which indicated that the both-mutant interaction made the leading contribution. In GBM, LUSC, and UCS, the significant difference of hazard ratio between TP53-only-mutant group and PIK3CA-only-mutant group was neutralized in the both-mutant group, to some extent equivalent to “average effect (OS curve of double-mutant group was between that of only single gene mutant groups)". For PIK3CA-TP53 in HNSC, both-mutant group and TP53-only-mutant group carried with a higher hazard ratio than PIK3CA-only-mutant group. It suggested that the increasing hazard ratio in both-mutant group might be resulted from TP53 mutation. For the circumstance in UCEC, TP53 and PIK3CA were testified to be correlated with higher and lower hazard ratio, respectively and both-mutant group and TP53-only-mutant group both with significantly higher hazard ratio than PIK3CA-only-mutant group, which further verified the greater strength of TP53 than PIK3CA in both-mutant group. Conclusions: In summary, our study identified PIK3CA-TP53 co-mutation as a predictor of OS in seven cancer types: GBM, HNSC, LUSC, SARC, SKCM, UCEC, and UCS, especially in SARC and SKCM.

scholarly journals THE SHORTEN LIFE EXPECTANCY IN WORKERS IN RELATION TO DIFFERENT HISTOLOGICAL TYPES OF LUNG CANCER AND ABSORBED DOSE TO LUNGS FROM PLUTONIUM-239

2018 ◽  
Vol 97 (2) ◽  
pp. 174-178
Author(s):  
Vitaly I. Telnov ◽  
F. D. Tretyakov ◽  
P. V. Okatenko
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Mortality Rate ◽  
Life Expectancy ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Absorbed Dose ◽  
Years Of Life Lost ◽  
Histological Types ◽  
Cancer Types

The assessment of the effect of incorporated Plutonium-239 on the life expectancy in Mayak PA employees was executed on the basis of the analysis of the mortality rate and the age of death in relation to different histological types of lung cancer as lungs is one of the main organs of deposition of the nuclide. 2321 male workers of Mayak PA employed in 1948-1958 (1709 deceased and 612 alive) were included in the analysis. For different histological types, the values of the decline of life expectancy (proportion of workers that failed to attain the age of 65 years and potential years of life lost) in Mayak PA workers that had died from lung cancer were assessed in relation to incorporated Plutonium-239. As a result of the study of the reduction in the life expectancy, the increase in the number of workers that failed to attain the age of 65 years and the gain in potential years of life lost in Mayak PA workers that had died from lung cancer with absorbed dose to lungs from Plutonium-239 exceeding 1cGy was observed in relation to all the known histological types of lung cancer such as adenocarcinoma, squamous cell carcinoma and other epithelial neoplasms. However, according to the relative risk for changes observed, these effects were three times more clearly marked in the case of adenocarcinoma in comparison to other histological types of lung cancer. Such significant decline in the life expectancy in the case of adenocarcinoma was detected by both the increased mortality rate and a larger amount of untimely deaths i.e. the decreased age of the death. The comprising of life expectancy in the case of squamous cell carcinoma was less significant and was mostly detected relying upon the increased mortality rate and non-reliable trend for untimely deaths. In relation to other types of epithelial cancer, the decline in life expectancy was approximately the same as in the case of squamous cell carcinoma, though in contrast to the latter it was determined due to the increased mortality rate only. The results obtained lay the foundation for the basis for, in the first place, the comparative quantitative assessment of the contribution of increased mortality and untimely death rate to the decline in life expectancy in relation to different histological lung cancer types among Mayak PA workers, and, in the second place, for evaluation of health damage based on person-years of life lost.

scholarly journals Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Xi-Lei Zhou ◽  
Chang-Hua Yu ◽  
Wan-Wei Wang ◽  
Fu-Zhi Ji ◽  
Yao-Zu Xiong ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Adverse Events ◽  
Esophageal Squamous Cell Carcinoma ◽  
Elderly Patients ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Concurrent Chemoradiotherapy ◽  
Response Rate ◽  
Locally Advanced ◽  
Grade 3

Abstract Background This retrospective study was to assess and compare the toxicity and efficacy of concurrent chemoradiotherapy (CCRT) with S-1 or docetaxel and cisplatin in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Methods Patients with locally advanced ESCC who received CCRT with S-1 (70 mg/m2 twice daily on days 1–14, every 3 weeks for 2 cycles, S-1 group) or docetaxel (25 mg/m2) and cisplatin (25 mg/m2) on day 1 weekly (DP group) between 2014 and 2016 were retrospectively analyzed. Radiotherapy was delivered in 1.8–2.0 Gy per fraction to a total dose of 50–60 Gy. Treatment-related toxicities (Common Terminology Criteria for Adverse Events version 4.0), response rate, and survival outcomes were compared between groups. Results A total of 175 patients were included in this study (72 in the S-1 group and 103 in the DP group). Baseline characteristics were well balanced between the two groups. The incidence of grade 3–4 adverse events were significantly lower in the S-1 group than that of the DP group (22.2% vs. 45.6%, p = 0.002). In the DP group, elderly patients (> 60 years) had a significantly higher rate of grade 3–4 adverse events than younger patients (58.1% vs. 31.3%, p = 0.01). The objective overall response rate (complete response + partial response) was 68.1% in the S-1 group, and 73.8% the DP group (p = 0.497). The 3-year overall survival was 34.7% in the S-1 group, and 38.8% in the DP group (p = 0.422). The 3-year progression free survival in the DP group was higher than that in the S-1 group but without significant difference (33.0% vs. 25.0%, p = 0.275). Conclusion CCRT with S-1 is not inferior to CCRT with docetaxel and cisplatin and is better tolerated in in elderly patients with locally advanced ESCC.

A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer

2007 ◽  
Vol 25 (2) ◽  
pp. 187-189 ◽  
Author(s):  
Katsunori Kagohashi ◽  
Hiroaki Satoh ◽  
Hiroichi Ishikawa ◽  
Morio Ohtsuka ◽  
Kiyohisa Sekizawa
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Serum Marker ◽  
Small Cell ◽  
Squamous Cell Carcinoma Antigen ◽  
Small Cell Lung

scholarly journals Second Cancers After Squamous Cell Carcinoma and Adenocarcinoma of the Cervix

2009 ◽  
Vol 27 (6) ◽  
pp. 967-973 ◽  
Author(s):  
Anil K. Chaturvedi ◽  
Ruth A. Kleinerman ◽  
Allan Hildesheim ◽  
Ethel S. Gilbert ◽  
Hans Storm ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
General Population ◽  
Cancer Risk ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lung Cancer Risk ◽  
Second Cancer ◽  
Second Cancers ◽  
Second Cancer Risk

Purpose Although cervical squamous cell carcinoma (SCC) and adenocarcinoma (AC) are both caused by human papillomavirus (HPV) infection, they differ in cofactors such as cigarette smoking. We assessed whether these cofactor differences translate into differences in second cancer risk. Patients and Methods We assessed second cancer risk among 85,109 cervical SCC and 10,280 AC survivors reported to population-based cancer registries in Denmark, Finland, Norway, Sweden, and the United States. Risks compared to the general population were assessed using standardized incidence ratios (SIR). Results Overall cancer risk was significantly increased among both cervical SCC survivors (n = 10,559 second cancers; SIR, 1.31; 95% CI, 1.29 to 1.34) and AC survivors (n = 920 second cancers; SIR, 1.29; 95% CI, 1.22 to 1.38). Risks of HPV-related and radiation-related cancers were increased to a similar extent among cervical SCC and AC survivors. Although significantly increased in both groups when compared with the general population, risk of smoking-related cancers was significantly higher among cervical SCC than AC survivors (P = .015; SIR for cervical SCC = 2.07 v AC = 1.78). This difference was limited to lung cancer (SIR for cervical SCC = 2.69 v AC = 2.18; P = .026). The increased lung cancer risk among cervical AC survivors was observed for both lung SCC and lung AC. SIRs for second cancers of the colon, soft tissue, melanoma, and non-Hodgkin's lymphoma were significantly higher among cervical AC than SCC survivors. Conclusion The second cancer profiles among cervical SCC and AC survivors mirror the similarities and differences in cofactors for these two histologies. Because smoking is not a cofactor for cervical AC, the increased lung cancer risk suggests a role for additional factors.

scholarly journals Transbronchial Dissemination of Squamous Cell Lung Cancer

2015 ◽  
Vol 9 ◽  
pp. CMO.S32707 ◽  
Author(s):  
Akira Tadokoro ◽  
Nobuhiro Kanaji ◽  
Tomoya Ishii ◽  
Naoki Watanabe ◽  
Takuya Inoue ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Alternative Pathway ◽  
Histological Type ◽  
Squamous Cell Lung Cancer ◽  
Smoking History ◽  
Endobronchial Metastasis

We report a case of squamous cell lung cancer with transbronchial dissemination in a 73-year-old man. Bronchoscopic examination revealed multiple bronchial mucosal nodules that existed independently of one another. We reviewed 16 previous cases of endobronchial metastasis in lung cancer. All patients were men. Among the reports that described the smoking history, most patients were smokers (6/7), and the most frequent histological type of cancer was squamous cell carcinoma (11/17). Although hematogenous and lymphogenous routes have been reported as metastatic mechanisms, no previous cases involving transbronchial dissemination have been described. Transbronchial dissemination may be an alternative pathway of endobronchial metastasis.

scholarly journals Epidemiologic trends in lung cancer over two decades in Northern Greece: an analysis of bronchoscopic data

2016 ◽  
Vol 71 (4) ◽  
Author(s):  
T. Kontakiotis ◽  
N. Manolakoglou ◽  
F. Zoglopitis ◽  
D. Iakovidis ◽  
L. Sacas ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Northern Greece ◽  
Female Ratio

Background and Aim. The relative frequency of histological subtypes of lung cancer in Europe has changed dramatically during the 20th century. The aim of this study was to explore the changing epidemiology of lung cancer in Northern Greece over the last two decades. Methods. From the extensive database of the Bronchoscopy Unit of the G. Papanicolaou General Hospital, Thessaloniki, Greece, we identified all patients with a histologic and/or cytologic report positive for lung cancer over two consecutive decades. Results. Between 1/1/1986 and 31/12/2005 we identified 9981 patients with specimens positive for lung cancer. A significant increase in mean patient age was observed during the second decade (64.8±9.4 vs. 62.1±8.9, p=0.001). Men developed lung cancer ten times more often than women. The predominant histological type was squamous cell cancer in males (4203 cases, 45.7%) and adenocarcinoma (418 cases, 52.6%) in females. The number of lung cancer cases was significantly higher during the second decade compared to the first decade (5766 cases [57.8%] vs. 4215 cases [42.2%], respectively, p&lt;0.001). There was a significant decrease in the percentage of squamous cell carcinoma in males in the second decade (2317 cases [44.1%] vs. 1886 cases [48.0%], p&lt;0.001), and an increase in adenocarcinoma (1021 cases [19.4%] vs. 609 [11.6%], p&lt;0.001). In females, the relative incidence of adenocarcinoma was decreased and that of squamous cell carcinoma was increased, but not significantly. There was no obvious change in the incidence of small cell lung cancer. Neoplastic lesions were most often located in the upper lobes. Conclusion. The number of lung cancer cases has increased in the last decade. Squamous lung cancer appears to be decreasing in men and increasing in women. Adenocarcinoma appears to be increasing in men and decreasing in women. There appears to be no change in small cell lung cancer. During the second decade there has been a significant decrease in the male: female ratio.

Sign in / Sign up

Export Citation Format

Share Document